Membership Directory

Advanced Cell Technology

Category: Drug Development
Phone: +1 (508) 756-1212
Fax: +1 (508) 756-4468
Website: http://www.advancedcell.com
Location: Marlborough, MA
Therapeutic Areas: Blood Disorder, Musculoskeletal, Ophthalmology

Advanced Cell Technology, Inc. (OTCBB:ACTC – News) is applying stem cell technology in the field of regenerative medicine to bring effective, patient-specific therapies to the bedside. The company’s Myoblast program is an autologous adult stem cell therapy for the treatment of heart disease. The Myoblast program has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials shortly. The company is also rapidly moving towards human clinical trials for its embryonic stem cell therapies including its RPE and HG programs. ACT published positive data from animal studies for its RPE (retinal pigment epithelial) cell program for the treatment of retinal degenerative disorders completed in collaboration with the Casey Eye Institute at Oregon Health and Science University. The company also has GLP Safety Studies in process for its RPE Program. ACT published positive data in the journal NATURE Methods for its HG (hemangioblast) cell program for the treatment of blood and cardiovascular diseases. In August 2006, ACT announced a novel technique to generate embryonic stem cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Less than one year later, the company announced the creation of a human embryonic stem cell line without destroying the embryo. ACT owns or licenses over 380 patents and patent applications.